The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...

Artificial Intelligence (AI) can play a crucial role in drug discovery, but the lack of sufficient data in this area remains ...

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves three-year disease-free survival (96%) in children with standard-risk B-cell acute lymphoblastic leukemia (B-ALL), reducing ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

We have honored to host Dr. Sara Naseri, CEO and Co-Founder of Qvin, a pioneering figure in women’s health innovation. In this session, we explore the groundbreaking Q-Pad technology, the first ...

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...

We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the groundbreaking advancements of GIGA-2339, the first recombinant polyclonal drug ...

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven biological research, in a strategic equity partnership aimed at ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer.